Amado R. G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D. J. et al. 2023 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 41, 3278–3286.

Article  PubMed  Google Scholar 

Andreyev H. J., Norman A. R., Cunningham D., Oates J., Dix B. R., Iacopetta B. J. et al. 2001 Kirsten ras mutations in patients with colorectal cancer: the “RASCAL II” study. Br. J. Cancer 85, 692–696.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardelli A. and Siena S. 2010 Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254–1261.

Article  CAS  PubMed  Google Scholar 

Cai L., Qin X., Xu Z., Song Y., Jiang H., Wu Y. et al. 2019 Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method. ACS Omega 4, 12036–12042.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chinnappan D., Xiao D., Ratnasari A., Andry C., King T. C. and Weber H. C. 2009 Transcription factor YY1 expression in human gastrointestinal cancer cells. Int. J. Oncol. 34, 1417–1423.

CAS  PubMed  Google Scholar 

Donovan S., Shannon K. M. and Bollag G. 2002 GTPase activating proteins: critical regulators of intracellular signaling. Biochim. Biophys. Acta 1602, 23–45.

CAS  PubMed  Google Scholar 

Fondevila F., Fernández-Palanca P., Méndez-Blanco C., Payo-Serafín T., Lozano E., Marin J. J. G. et al. 2021 Association of FOXO3 expression with tumor pathogenesis, prognosis and clinicopathological features in hepatocellular carcinoma: A systematic review with meta-analysis. Cancers (Basel) 13.

Fung A. S., Karimi M., Michiels S., Seymour L., Brambilla E., Le-Chevalier T. et al. 2021 Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. Transl. Lung Cancer Res. 10, 826–838.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hays E. and Bonavida B. 2019 YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resist. Updat. 43, 10–28.

Article  PubMed  Google Scholar 

Hossain M. S., Karuniawati H., Jairoun A. A., Urbi Z., Ooi J., John A. et al. 2022 Colorectal cancer: A review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel), 14.

Kato K., Cox A. D., Hisaka M. M., Graham S. M., Buss J. E. and Der C. J. 1992 Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA 89, 6403–6407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim S. T., Lim D. H., Jang K. T., Lim T., Lee J., Choi Y. L. et al. 2011 Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol. Cancer Ther. 10, 1993–1999.

Article  CAS  PubMed  Google Scholar 

Kim S., Kim N., Kang K., Kim W., Won J. and Cho J. 2019 Whole transcriptome analysis identifies TNS4 as a key effector of cetuximab and a regulator of the oncogenic activity of KRAS mutant colorectal cancer cell lines. Cells 8.

Lee K. W., Lee S. S., Kim S. B., Sohn B. H., Lee H. S., Jang H. J. et al. 2015 Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin. Cancer Res. 21, 357–364.

Article  CAS  PubMed  Google Scholar 

Lin C. C., Kuo I. Y., Wu L. T., Kuan W. H., Liao S. Y., Jen J. et al. 2020 Dysregulated Kras/YY1/ZNF322A/Shh transcriptional axis enhances neo-angiogenesis to promote lung cancer progression. Theranostics 10, 10001–10015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Livak K. J. and Schmittgen T. D. 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402–408.

Article  CAS  PubMed  Google Scholar 

Martinez-Paniagua M. A., Vega M. I., Huerta-Yepez S., Baritaki S., Vega G. G., Hariharan K. et al. 2012 Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs. Mol. Cancer Ther. 11, 572–581.

Article  CAS  PubMed  Google Scholar 

Mcfall T., Diedrich J. K., Mengistu M., Littlechild S. L., Paskvan K. V., Sisk-Hackworth L. et al. 2019 A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. Sci. Signal. 12.

Meliala I. T. S., Hosea R., Kasim V. and Wu S. 2020 The biological implications of Yin Yang 1 in the hallmarks of cancer. Theranostics 10, 4183–4200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morgan E., Arnold M., Gini A., Lorenzoni V., Cabasag C. J., Laversanne M. et al. 2023 Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72, 338–344.

Article  PubMed  Google Scholar 

Morris V. K., Kennedy E. B., Baxter N. N., Benson A. B. III., Cercek A., Cho M. et al. 2023 Treatment of metastatic colorectal cancer: ASCO guideline. J. Clin. Oncol. 41, 678–700.

Article  PubMed  Google Scholar 

Nan X., Tamgüney T. M., Collisson E. A., Lin L. J., Pitt C., Galeas J. et al. 2015 Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc. Natl. Acad. Sci. USA 112, 7996–8001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ostrem J. M., Peters U., Sos M. L., Wells J. A. and Shokat K. M. 2013 K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parikh K., Banna G., Liu S. V., Friedlaender A., Desai A., Subbiah V. et al. 2022 Drugging KRAS: current perspectives and state-of-art review. J. Hematol. Oncol. 15, 22.

Article  Google Scholar 

Schubbert S., Shannon K. and Bollag G. 2007 Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7, 295–308.

Article  CAS  PubMed  Google Scholar 

Shaib W., Mahajan R. and El-Rayes B. 2013 Markers of resistance to anti-EGFR therapy in colorectal cancer. J. Gastrointest. Oncol. 4, 308–318.

CAS  PubMed  PubMed Central  Google Scholar 

Shao Z., Yang W., Meng X., Li M., Hou P., Li Z. et al. 2023 The role of transcription factor Yin Yang-1 in colorectal cancer. Cancer Med. 12, 11177–11190.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siddiqui A. D. and Piperdi B. 2010 KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann. Surg. Oncol. 17, 1168–1176.

Article  PubMed  Google Scholar 

Spano J. P., Fagard R., Soria J. C., Rixe O., Khayat D. and Milano G. 2005 Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann. Oncol. 16, 189–194.

Article  CAS  PubMed  Google Scholar 

Troiani T., Martinelli E., Napolitano S., Vitagliano D., Ciuffreda L. P., Costantino S. et al. 2013 Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin. Cancer Res. 19, 6751–6765.

Article  CAS  PubMed  Google Scholar 

Van Emburgh B. O., Sartore-Bianchi A., Di Nicolantonio F., Siena S. and Bardelli A. 2014 Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol. Oncol. 8, 1084–1094.

Article  PubMed  PubMed Central  Google Scholar 

Wang D., Wang B., Wang R., Zhang Z., Lin Y., Huang G. et al. 2017 High expression of EGFR predicts poor survival in patients with resected T3 stage gastric adenocarcinoma and promotes cancer cell survival. Oncol. Lett. 13, 3003–3013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wee P. and Wang Z. 2017 Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 9.

Yuan P., He X. H., Rong Y. F., Cao J., Li Y., Hu Y. P. et al. 2017 KRAS/NF-κB/YY1/miR-489 Signaling axis controls pancreatic cancer metastasis. Cancer Res. 77, 100–111.

Article  CAS  PubMed  Google Scholar 

Zhang J., Antonyak M. A., Singh G. and Cerione R. A. 2013a A mechanism for the upregulation of EGF receptor levels in glioblastomas. Cell Rep. 3, 2008–2020.

Article